<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="37921">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02612857</url>
  </required_header>
  <id_info>
    <org_study_id>8400-211</org_study_id>
    <nct_id>NCT02612857</nct_id>
  </id_info>
  <brief_title>Trial of IMO-8400 in Adult Patients With Dermatomyositis</brief_title>
  <acronym>8400-211</acronym>
  <official_title>A Phase 2, Randomized, Double-Blind, Placebo-Controlled Trial of IMO-8400 in Patients With Dermatomyositis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Idera Pharmaceuticals, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Idera Pharmaceuticals, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine how safe and effective IMO-8400 is in adults with
      dermatomyositis.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study will evaluate the safety and efficacy of IMO-8400 in adults with active
      dermatomyositis (DM).
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>November 2015</start_date>
  <completion_date type="Anticipated">August 2017</completion_date>
  <primary_completion_date type="Anticipated">August 2017</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Participant, Care Provider, Investigator</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence and frequency of adverse events, injection site reaction, physical exam and laboratory exam findings with escalating dose levels of IMO-8400</measure>
    <time_frame>28 weeks (24 weeks treatment + 4 weeks follow up)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change from baseline in CDASI Activity score</measure>
    <time_frame>28 weeks (24 weeks treatment + 4 weeks follow up)</time_frame>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">36</enrollment>
  <condition>Dermatomyositis</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>normal saline subcutaneous injections once a week for 24 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>IMO-8400 Dose Group 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>IMO-8400 Dose Group 1 subcutaneous injections once a week for 24 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>IMO-8400 Dose Group 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>IMO-8400 Dose Group 2 subcutaneous injections once a week for 24 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>IMO-8400 Dose Group 1</intervention_name>
    <description>IMO-8400 Dose 1 subcutaneous injections once a week for 24 weeks.</description>
    <arm_group_label>IMO-8400 Dose Group 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>IMO-8400 Dose Group 2</intervention_name>
    <description>IMO-8400 Dose 2 subcutaneous injections once a week for 24 weeks.</description>
    <arm_group_label>IMO-8400 Dose Group 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>normal saline subcutaneous injections once a week for 24 weeks.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Has definite or probable DM based on the criteria of Bohan and Peter

          -  Has a Cutaneous Dermatomyositis Disease Area and Severity Index (CDASI)-Activity
             score â‰¥15

          -  Patients with muscle weakness are eligible; however having muscle weakness is not
             mandatory.

          -  Study participants must have a diagnostic evaluation for cancer if the diagnosis of
             DM was within 2 years prior to the Screening Visit

        Exclusion Criteria:

          -  Has ongoing severe dysphagia (e.g., requires a feeding tube) for the 3 months prior
             to Screening

          -  Has known hypersensitivity to any oligodeoxynucleotide

          -  Has a history of drug or alcohol abuse within one year of screening, or evidence of
             drug abuse by urine drug screening

          -  Has body weight &gt;140 kg

          -  Has a diagnosis of Juvenile DM, IBM, drug-induced toxic myopathy, metabolic myopathy,
             dystrophy, cancer-associated DM, or connective tissue disease-associated DM (e.g.,
             overlap syndrome)

          -  Has received one or more of following prohibited treatments within the interval noted
             prior to Screening (Visit 1):

               1. Rituximab within 24 weeks (Note: patients who received rituximab are only
                  eligible for inclusion if B-cell counts are confirmed to be within normal
                  limits)

               2. Intravenous corticosteroids within 12 weeks

               3. Antimalarials (e.g., hydroxychloroquine) within 36 weeks

               4. Topical corticosteroids (excluding scalp) within 2 weeks

          -  Has evidence of or has required treatment for cancer (except for treated,
             non-invasive carcinoma of the skin or cured cervical carcinoma-in-situ) within 5
             years

          -  Has interstitial lung disease requiring the use of supplemental oxygen
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Joanna Horobin, MD</last_name>
    <role>Study Director</role>
    <affiliation>Idera Pharmaceuticals</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Idera Study Monitor</last_name>
    <phone>1-877-888-6550</phone>
    <phone_ext>2</phone_ext>
    <email>patientinfo@iderapharma.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of Alabama</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35210</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Phoenix Neurological Associates</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85018</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Todd Levine, MD</last_name>
      <phone>602-288-4673</phone>
      <email>todd.levine@hriaz.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of California, Irvine</name>
      <address>
        <city>Irvine</city>
        <state>California</state>
        <zip>92697</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Brian Minton, CRC</last_name>
      <phone>714-456-8520</phone>
      <email>bminton@uci.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Stanford Hospital and Clinics</name>
      <address>
        <city>Stanford</city>
        <state>California</state>
        <zip>94063</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Joel Nicholus, MA, CCRC</last_name>
      <phone>650-725-4612</phone>
      <email>nicholus@stanford.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>George Washington University</name>
      <address>
        <city>Washington, D.C.</city>
        <state>District of Columbia</state>
        <zip>20052</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of Miami</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bethly Aubourg</last_name>
      <phone>305-243-8567</phone>
      <email>baubourg@med.miami.edu</email>
    </contact>
    <investigator>
      <last_name>Dana P. Ascherman, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Northwestern University</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Erika Hagstrom</last_name>
      <phone>312-503-5906</phone>
      <email>Erika.hagstrom@northwestern.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Kansas</name>
      <address>
        <city>Kansas City</city>
        <state>Kansas</state>
        <zip>66160</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christy Nichols, RN</last_name>
      <phone>913-945-9945</phone>
      <email>Cnichols2@kumc.edu</email>
    </contact>
    <investigator>
      <last_name>Mazen Dimachkie, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Johns Hopkins University</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21224</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lisa Christopher-Stine, MD, MPH</last_name>
      <phone>410-550-1741</phone>
      <email>myositisresearch@jhmi.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Brigham and Women's Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kristen Roe</last_name>
      <phone>617-525-6763</phone>
      <email>kroe@partners.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Michigan</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48109</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jeff Sarazin</last_name>
      <phone>734-998-1271</phone>
      <email>jsarazin@med.umich.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Washington University</name>
      <address>
        <city>St. Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Northwell Health</name>
      <address>
        <city>Great Neck</city>
        <state>New York</state>
        <zip>11021</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michelle King-Rosario</last_name>
      <phone>516-708-2557</phone>
      <email>mkong@northwell.edu</email>
    </contact>
    <investigator>
      <last_name>Galina Marder, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ohio State University</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43210</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ifeanyi Okoh</last_name>
      <phone>614-688-7837</phone>
      <email>Ifeanyi.okoh@osumc.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Pittsburgh</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15261</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Diane Koontz</last_name>
      <phone>412-383-8674</phone>
      <email>dik4@pitt.edu</email>
    </contact>
    <investigator>
      <last_name>Chester Oddis, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Rohit Aggarwal, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Medical University of South Carolina</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>29425</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christine Hudson</last_name>
      <phone>843-792-3790</phone>
      <email>hudsoncm@musc.edu</email>
    </contact>
    <investigator>
      <last_name>Katherine Ruzhansky, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Vermont College of Medicine</name>
      <address>
        <city>Burlington</city>
        <state>Vermont</state>
        <zip>05405</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Shannon Lucy</last_name>
      <phone>802-656-4582</phone>
      <email>shannon.lucy@med.uvm.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Debrecen</name>
      <address>
        <city>Debrecen</city>
        <zip>H-4032</zip>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Katalin Danko, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>MRC/ARUK Institute of Ageing and Chronic Disease, University of Liverpool</name>
      <address>
        <city>Liverpool</city>
        <zip>L7 8TX</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Robert Cooper, MD</last_name>
      <phone>+44 151 794 9133</phone>
      <email>Robert.Cooper@liverpool.ac.uk</email>
    </contact>
    <investigator>
      <last_name>Robert Cooper, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Kings College London, Academic Department of Rheumatology</name>
      <address>
        <city>London</city>
        <zip>SE5 9RJ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>University College London Hospital</name>
      <address>
        <city>London</city>
        <zip>WC1E6JF</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>David Isenberg, MD</last_name>
      <phone>+44 203 108 2150</phone>
      <email>e.geary@ucl.ac.uk</email>
    </contact>
  </location>
  <location_countries>
    <country>Hungary</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2017</verification_date>
  <lastchanged_date>March 30, 2017</lastchanged_date>
  <firstreceived_date>November 18, 2015</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>dermatomyositis</keyword>
  <keyword>IMO-8400</keyword>
  <keyword>Pioneer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Dermatomyositis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
